- Home
- ADEA vs CDTX Comparison
ADEA vs CDTX Comparison
Compare ADEA & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- CDTX
- Stock Information
- Founded
- ADEA 1990
- CDTX 2012
- Country
- ADEA United States
- CDTX United States
- Employees
- ADEA N/A
- CDTX N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADEA Technology
- CDTX Health Care
- Exchange
- ADEA Nasdaq
- CDTX Nasdaq
- Market Cap
- ADEA 1.8B
- CDTX 1.6B
- IPO Year
- ADEA N/A
- CDTX 2015
- Fundamental
- Price
- ADEA $16.73
- CDTX $111.89
- Analyst Decision
- ADEA Strong Buy
- CDTX Strong Buy
- Analyst Count
- ADEA 4
- CDTX 12
- Target Price
- ADEA $19.50
- CDTX $112.00
- AVG Volume (30 Days)
- ADEA 597.7K
- CDTX 1.3M
- Earning Date
- ADEA 11-06-2025
- CDTX 11-06-2025
- Dividend Yield
- ADEA 1.27%
- CDTX N/A
- EPS Growth
- ADEA 80.44
- CDTX N/A
- EPS
- ADEA 0.74
- CDTX N/A
- Revenue
- ADEA $378,674,000.00
- CDTX N/A
- Revenue This Year
- ADEA $9.49
- CDTX N/A
- Revenue Next Year
- ADEA $4.94
- CDTX N/A
- P/E Ratio
- ADEA $21.29
- CDTX N/A
- Revenue Growth
- ADEA 5.47
- CDTX N/A
- 52 Week Low
- ADEA $10.59
- CDTX $10.14
- 52 Week High
- ADEA $18.25
- CDTX $121.21
- Technical
- Relative Strength Index (RSI)
- ADEA 54.36
- CDTX 72.11
- Support Level
- ADEA $15.56
- CDTX $109.36
- Resistance Level
- ADEA $18.25
- CDTX $121.21
- Average True Range (ATR)
- ADEA 0.69
- CDTX 6.82
- MACD
- ADEA -0.18
- CDTX 1.56
- Stochastic Oscillator
- ADEA 45.71
- CDTX 75.55
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.